You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, T-Cell

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma Trial in New York, Columbus (Ibrutinib)

Active, not recruiting
  • T-cell Lymphoma
  • Relapsed and Refractory T-cell Lymphoma
  • New York, New York
  • +1 more
Nov 8, 2022

T-cell Non-Hodgkin Lymphoma Trial in Boston (Cyclophosphamide, Doxorubicin, Vincristine)

Terminated
Has Results
  • T-cell Non-Hodgkin Lymphoma
  • Boston, Massachusetts
  • +1 more
Jan 26, 2023

Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)

Enrolling by invitation
  • Peripheral T-cell Lymphoma Targeted Therapy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023

Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United

Recruiting
  • Folliculotropic Mycosis Fungoides
  • +7 more
  • Durvalumab
  • +2 more
  • Duarte, California
  • +3 more
Jan 12, 2023

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Previously Untreated Peripheral T-cell Lymphoma Trial in Tampa, Saint Louis, New York (CC-486 Administration, CHOP

Active, not recruiting
Has Results
  • Previously Untreated Peripheral T-cell Lymphoma
  • CC-486 Administration
  • CHOP Administration
  • Tampa, Florida
  • +3 more
Jan 18, 2023

Autologous Stem Cell Transplantation, Conditioning Trial in Xi'an (modified BEAM, BEAM)

Not yet recruiting
  • Autologous Stem Cell Transplantation
  • Conditioning
  • Xi'an, Shaanxi, China
    First Affiliated Hospital of Xian Jiaotong University
Apr 14, 2023

T-Cell Lymphoma Trial (Brentuximab vedotin)

Not yet recruiting
  • T-Cell Lymphoma
  • Brentuximab vedotin
  • (no location specified)
Jun 30, 2022

Cutaneous T-Cell Lymphoma/Mycosis Fungoides Trial in Fairport (Hypericin)

Completed
  • Cutaneous T-Cell Lymphoma/Mycosis Fungoides
  • Fairport, New York
    Rochester Skin Lymphoma Medical Group
Aug 24, 2022

Allo-HSCT as First-line Consolidation in High-risk PTCL

Recruiting
  • T Cell Lymphoma
    • Beijing, China
      Peking University People's Hospital
    Jul 31, 2022

    T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

    Not yet recruiting
    • T-Cell Lymphoma
    • (no location specified)
    Jul 22, 2022

    Cutaneous T Cell Lymphoma, Mycosis Fungoides Trial (Mogamulizumab, Brentuximab vedotin)

    Not yet recruiting
    • Cutaneous T Cell Lymphoma
    • Mycosis Fungoides
    • (no location specified)
    Dec 7, 2022

    T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

    Recruiting
    • T Lymphoblastic Leukemia/Lymphoma
    • +4 more
    • anti-CD7 CAR-T cells
    • Shanghai, China
      Xianmin General Song
    Aug 29, 2022

    Peripheral T Cell Lymphoma Trial in Harlingen (Belinostat Injection, Pralatrexate Injection, CHOP)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • Belinostat Injection
    • +3 more
    • Harlingen, Texas
      Valley Cancer Associates
    Oct 16, 2023

    T Cell Lymphoma Trial in Shanghai (Chidamide combined with BEAM)

    Recruiting
    • T Cell Lymphoma
    • Chidamide combined with BEAM
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Sep 27, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

    Not yet recruiting
    • Adult T-cell Leukemia/Lymphoma
    • +4 more
    • CC-486 (5-azacitidine)
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 17, 2022

    Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

    Not yet recruiting
    • Cutaneous T Cell Lymphoma
    • +2 more
      • Ancona, Italy
      • +19 more
      Nov 2, 2023

      Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL) Trial in United States (SIM1811-03)

      Recruiting
      • Advanced Solid Tumor
      • Cutaneous T-cell Lymphoma (CTCL)
      • Detroit, Michigan
      • +5 more
      Oct 6, 2022

      Lymphoma Trial (Tislelizumab)

      Not yet recruiting
      • Lymphoma
      • (no location specified)
      Jul 28, 2022

      Peripheral T-cell Lymphoma Trial in Tianjin (Lposomal mitoxantrone HCl,Cyclophosphamide,Vincristine,Etoposide and

      Not yet recruiting
      • Peripheral T-cell Lymphoma
      • Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Insititute & Hospital
      Jul 13, 2022

      Venetoclax Tablets Crushed and Dissolved Into a Solution

      Not yet recruiting
      • Hematologic Malignancy
      • +18 more
      • 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
      • Cincinnati, Ohio
        Cincinnati Children's Hospital Medical Center
      Nov 8, 2023

      (CHANT)Real World Study of Duvelisib in Treatment of

      Not yet recruiting
      • Follicular Lymphoma
      • +5 more
      • (no location specified)
      Jun 20, 2023